Search Within

Gary Schwartz

  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (8)
Groups
  1. Department of Medicine (18)
  2. Genitourinary Oncology Service (18)
  3. Solid Tumor Oncology Division (18)
  4. Biostatistics Service (9)
  5. Epidemiology and Biostatistics (9)
  6. GSK Faculty (9)

More Groups

People
  1. Dana Rathkopf (8)
  2. Manish Shah (6)
  3. Richard Carvajal (6)
  4. David Solit (5)
  5. Mark Dickson (5)
  6. David Kelsen (4)

More People

Years
  1. 2014 (2)
  2. 2013 (3)
  3. 2011 (2)
  4. 2010 (2)
  5. 2009 (1)
  6. 2007 (1)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Clinical Cancer Research (4)
  3. Proceedings of the American Association for Cancer Research Annual Meeting (2)
  4. Annals of Oncology (1)
  5. Cancer Chemotherapy and Pharmacology (1)
  6. Cancer Discovery (1)

More Publications

Publishers
  1. American Association for Cancer Research (8)
  2. American Society of Clinical Oncology (6)
  3. Springer (2)
  4. John Wiley & Sons (1)
  5. Oxford University Press (1)

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy
    Journal Article

    Al-Ahmadie, H.; Iyer, G.; Hohl, M.; Asthana, S.; Inagaki, A.; Schultz, N.; Hanrahan, A. J.; Scott, S. N.; Brannon, A. R.; McDermott, G. C.; more...
    Cancer Discovery (2014)

    Fulltext@MSK | Save
  • Multicenter sequential phase II study of flavopiridol plus oxaliplatin (Alvocidib) with or without 5-FU and leucovorin (LV) for patients (pts) with refractory germ cell tumors (GCT) including late relapse (LR)
    Meeting Abstract

    Feldman, D. R.; Stadler, W. M.; Appleman, L. J.; Quinn, D. I.; Costello, B. A.; Schwartz, G. K.; Reuter, V. E.; Woo, K.; Patil, S.; Fusco, A.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets)
    Meeting Abstract

    Harding, J. J.; Catalanotti, F.; Yaqubie, A.; McDermott, G. C.; Kersellius, R.; Merghoub, T.; Carvajal, R. D.; D'Angelo, S. P.; Dickson, M. A.; Schwartz, G. K.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K- or NRAS-mutated melanoma
    Meeting Abstract

    Catalanotti, F.; Solit, D. B.; Pulitzer, M. P.; Berger, M. F.; Scott, S. N.; Iyriboz, T.; Lacouture, M. E.; Panageas, K. S.; Wolchok, J. D.; Carvajal, R. D.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma
    Journal Article

    Catalanotti, F.; Solit, D. B.; Pulitzer, M. P.; Berger, M. F.; Scott, S. N.; Iyriboz, T.; Lacouture, M. E.; Panageas, K. S.; Wolchok, J. D.; Carvajal, R. D.; more...
    Clinical Cancer Research (2013)

    Fulltext@MSK | Save
  • A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
    Journal Article

    Dickson, M. A.; Rathkopf, D. E.; Carvajal, R. D.; Grant, S.; Roberts, J. D.; Reid, J. M.; Ames, M. M.; McGovern, R. M.; Lefkowitz, R. A.; Gonen, M.; more...
    Investigational New Drugs (2011)

    Fulltext@MSK | Save
  • Preclinical study of treatment response in HCT-116 cells and xenografts with 1H-decoupled 31P MRS
    Journal Article

    Darpolor, M. M.; Kennealey, P. T.; Le, H. C.; Zakian, K. L.; Ackerstaff, E.; Rizwan, A.; Chen, J. H.; Sambol, E. B.; Schwartz, G. K.; Singer, S.; more...
    NMR in Biomedicine (2011)

    Fulltext@MSK | Save
  • Phase I trial of pulse-dose vorinostat with flavopiridol in solid tumors
    Meeting Abstract

    Dickson, M. A.; Rathkopf, D. E.; Grant, S.; Roberts, J. D.; Reid, J. M.; Ames, M. M.; McGovern, R. M.; Gonen, M.; Dials, H. J.; Schwartz, G. K.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
    Journal Article

    Dickson, M. A.; Shah, M. A.; Rathkopf, D.; Tse, A.; Carvajal, R. D.; Wu, N.; Lefkowitz, R. A.; Gonen, M.; Cane, L. M.; Dials, H. J.; more...
    Cancer Chemotherapy and Pharmacology (2010)

    Fulltext@MSK | Save
  • Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors
    Journal Article

    Rathkopf, D.; Dickson, M. A.; Feldman, D. R.; Carvajal, R. D.; Shah, M. A.; Wu, N.; Lefkowitz, R.; Gonen, M.; Cane, L. M.; Dials, H. J.; more...
    Clinical Cancer Research (2009)

    Fulltext@MSK | Save